Pharmaceutical company MSD is moving to the new Stockholm life science cluster.

The company has been located in Sollentuna, outside of Stockholm, for the last 25 years but will change locations to Hagastaden during the spring of 2015.

“For MSD in Sweden it is important to be part of the development of the new cluster as early as possible and get access to the dynamic and competence that is now gathered in a geographically limited area,” says Jacob Tellgren, CEO of MSD Sweden, in a press release.

Hagastaden is being developed in both Stockholm and Solna and will be integrated with Karolinska Instiutet and the new university hospital Nya Karolinska Solna that opens in 2016. Hagastaden is to become one of the world’s most prominent areas for life science.